Recent advances in HER2-targeted antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan (T-DXd), have demonstrated clinical efficacy in HER2-low breast cancer, underscoring the need for a deeper understanding of HER2 signaling in this subtype [41]. This evidence concerns the gene ERBB2 and breast carcinoma.